Abstract
Thalassemic patients, especially in limited resources settings, are prone to multi-transfusion acquired Hepatitis C virus (HCV). After the discovery of direct acting antivirals (DAAs), many programs were designed to achieve HCV eradication both on the macro-elimination and micro-elimination axes. Thalassemic patients are good candidates to be addressed by a unique HCV micro-elimination model since they face some challenges during their treatment journey. Some of these challenges are the young age at infection, frequent blood transfusion, polypharmacy, drug–drug interactions, pharmacokinetic considerations and the risk of reinfection. The available data of success rates of HCV cure in thalassemic patients alert that the success rate in thalassemic patients might be lower than that reported in general population. These factors make HCV micro-elimination model, a hurdle towards the 2030 world health organisation (WHO) HCV eradication plan.
Reference56 articles.
1. Centres for Disease Control and prevention (CDC), Thalassemia. 2017. Available from: https://www.cdc.gov/ncbddd/thalassemia/facts.html. Accessed: 15th of Octocer 2017
2. Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection. World Health Organisation (WHO). 2016. Availablle from: http://apps.who.int/iris/bitstream/10665/205035/1/9789241549615_eng.pdf?ua=1. Accessed: 15th of March 2017
3. Abdella, Y., Riedner, G., Hajjeh, R.,et al.Blood transfusion and hepatitis: what does it take to prevent new infections? Eastern Mediterranean Health Journal. 2018; 24(6):595-597
4. Rachmilewitz, E.A., Weizer-Stern, O., Adamsky, K.,et al.Role of iron in inducing oxidative stress in thalassemia: can it be prevented by inhibition of absorption and by antioxidants? Ann. N. Y. Acad. Sci. 2005; 1054(1):118-123
5. Jafri, W., Siddiqui, B. and Awan, S. HCV-discovery to elimination,“myth or reality”. J. Hepatoma Res. 2018; 4(54):1-8
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献